Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Biotech
Boehringer, Amgen scrap immunology assets, citing low potential
Phase 1 trials of BI's immune modulator and Amgen's ulcerative colitis small molecule have both been terminated.
Darren Incorvaia
Apr 14, 2026 4:00am
Spyre touts ph. 2 UC win as proof it could surpass Entyvio
Apr 13, 2026 9:55am
Merck hands over $20M in IBD target deal with Quotient
Mar 24, 2026 6:00am
Bourla says pipeline pruning is mostly done after 6 more culls
Feb 3, 2026 11:33am
Sanofi keeps mum on Denali pact after scrapping final RIPK1 drug
Jan 29, 2026 5:16am
Ose narrows focus to conserve cash at expense of wider pipeline
Dec 9, 2025 9:41am
